UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C.  20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported)    December 13, 2006

 

 

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

 

 

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

 

 

Registrant’s telephone number, including area code (301) 398-0000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 7.01               Regulation FD Disclosure.

MedImmune, Inc. and its Board of Directors have received correspondence from David A. Katz of Matrix Asset Advisors, Inc. suggesting that MedImmune consider a strategic sale.  The Board has considered this suggestion and continues to unanimously believe that the best way for MedImmune to deliver value to its shareholders is to continue to execute on its business plan.

 

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MedImmune, Inc.
Date: December 13, 2006		/s/: William C. Bertrand Jr., Esq.
		William C. Bertrand Jr., Esq.
		Senior Vice President and General Counsel